METLung: a disappointing result in a challenging patient population

The landscape of second line therapy and beyond for advanced non-small-cell lung cancer (NSCLC) continues to evolve. In addition to single agent chemotherapy following a platinum doublet, the use of second line tyrosine kinase inhibitors (TKIs) in patients with targetable molecular mutations, as well as the approval of programmed cell death 1 (PD-1) and programmed death ligands 1 (PDL-1) immunotherapies has greatly expanded the available options, making the clinical choice of a subsequent therapy increasingly complicated.